Trial
NCT05568225
A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Forma Therapeutics, Inc.
Collaborators
—
Condition
Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R
Intervention
Etavopivat
Why stopped
Futility assessment concluded low likelihood of the trial showing meaningful patient benefit.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-10-22